Summary
4′, 6-Dichloroflavan, a potent inhibitor of rhinovirus replicationin vitro, was tested in a double-blind placebo controlled volunteer trial for its protective effect against experimental rhinovirus infection. Dichloroflavan was given orally (1 mg/kg, 3 times per day) for 3 doses before, and 13 doses after intransasal challenge with rhinovirus type 9, a type known to be highly sensitive in tissue culture. A total of 63 volunteers were included in the analysis for efficacy.
Dichloroflavan did not produce any consistent or significant reduction in quantitative clinical or laboratory evidence of infection, and there was no apparent negative correlation of such data with drug concentrations in plasma. It is concluded that administration of dichloroflavan in the oral formulation tested is not of value in the treatment of human rhinovirus infection.
Keywords: Placebo, Infectious Disease, Protective Effect, Negative Correlation, Tissue Culture
Footnotes
With 1 Figure
References
- 1.Bauer D. J., Selway J. W. T., Batchelor J. F., Tisdale M., Caldwell I. C., Young D. A. B. 4′, 6, Dichloroflavan (BW 683) a new anti-rhinovirus compound. Nature. 1981;292:369–370. doi: 10.1038/292369a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Beare A. S., Reed S. E. The study of antiviral compounds in volunteers. In: Oxford J., editor. Chemoprophylaxis and viral infections of the respiratory tract. Cleveland: CRC Press; 1977. pp. 27–55. [Google Scholar]
- 3.Fowler, A. S. E., Freestone, D. S.: Personal Communication.
- 4.Horn M. E. C., Reed S. E., Taylor P. Role of viruses and bacteria in acute wheezy bronchitis in childhood: a study of sputum. Arch. Dis. Childhood. 1979;54:587–592. doi: 10.1136/adc.54.8.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Larson H. E., Reed S. E., Tyrrell D. A. J. Isolation of rhinoviruses and coronaviruses from 38 colds in adults. J. Med. Virol. 1980;5:221–229. doi: 10.1002/jmv.1890050306. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.McHardy V., Inglis J. M., Calder A., Crofton J. W., Grigg I., Ryland D. A., Taylor P., Chadwick M., Coombs B., Riddell R. W. A study of infective and other factors in exacerbations of chronic bronchitis. Brit. J. Dis. Chest. 1980;74:228–238. doi: 10.1016/0007-0971(80)90048-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Meddis R. Unified analysis of variance by ranks. Brit. J. Math. and Statist. Psych. 1980;33:84–98. [Google Scholar]
- 8.Phillpotts R. J., Jones R. W., DeLong D. C., Reed S. E., Wallace J., Tyrrell D. A. J. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981;ii:1342–1344. doi: 10.1016/s0140-6736(81)92520-4. [DOI] [PubMed] [Google Scholar]
- 9.Reed S. E., Craig J. W., Tyrrell D. A. J. Four compounds active against rhinovirus: Comparisonin vitro and in volunteers. J. Infect. Dis. 1976;133(Suppl.):A128–A135. doi: 10.1093/infdis/133.supplement_2.a128. [DOI] [PubMed] [Google Scholar]
- 10.Reed S. E. The assessment of antirhinoviral compounds with clinical potential. In: Collier L. H., Oxford J., editors. Developments in antiviral therapy. London: Academic Press; 1980. [Google Scholar]
- 11.Snedecor, G. W., Cochran, W. G.: In: Statistical methods, 111–113. Publ. Iowa State University 1976.